Leveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid Tumors

Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models

(2015) L. Zhang et al.   CLINICAL CANCER RESEARCH

Targeting Tumor Hypoxia With Hypoxia-Activated Prodrugs

(2015) Jen Jen Yeh et al.   JOURNAL OF CLINICAL ONCOLOGY

Evolution of acquired resistance to anti-cancer therapy

(2014) Jasmine Foo et al.   JOURNAL OF THEORETICAL BIOLOGY

Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy

(2013) Jasdeep K. Saggar et al.   INTERNATIONAL JOURNAL OF CANCER

Evolutionary dynamics of cancer in response to targeted combination therapy

(2013) Ivana Bozic et al.   eLife

Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia

(2013) Christopher P. Guise et al.   Chinese Journal of Cancer

Combined EGFR/MET or EGFR/HSP90 Inhibition Is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET

(2012) L. Xu et al.   CANCER RESEARCH

Effects of Pharmacokinetic Processes and Varied Dosing Schedules on the Dynamics of Acquired Resistance to Erlotinib in EGFR-Mutant Lung Cancer

(2012) Jasmine Foo et al.   Journal of Thoracic Oncology

Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

(2012) Andrew J. Weickhardt et al.   Journal of Thoracic Oncology

On the rapidity of antibiotic resistance evolution facilitated by a concentration gradient

(2012) R. Hermsen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer

(2011) A C Mita et al.   BRITISH JOURNAL OF CANCER

Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer

(2011) J. D. Sun et al.   CLINICAL CANCER RESEARCH

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies

(2011) G. J. Weiss et al.   CLINICAL CANCER RESEARCH

Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302

(2011) F. Meng et al.   MOLECULAR CANCER THERAPEUTICS

Evolutionary Modeling of Combination Treatment Strategies To Overcome Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

(2011) Shannon M. Mumenthaler et al.   MOLECULAR PHARMACEUTICS

Acceleration of Emergence of Bacterial Antibiotic Resistance in Connected Microenvironments

(2011) Q. Zhang et al.   SCIENCE

Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling

(2011) J. Chmielecki et al.   Science Translational Medicine

Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug

(2010) J. Hu et al.   BLOOD

The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents

(2010) Dietmar W. Siemann   CANCER TREATMENT REVIEWS

Optimizing Combination Therapies with Existing and Future CML Drugs

(2010) Allen A. Katouli et al.   PLoS One

Evolution of resistance to anti-cancer therapy during general dosing schedules

(2009) Jasmine Foo et al.   JOURNAL OF THEORETICAL BIOLOGY

Combination of Two but Not Three Current Targeted Drugs Can Improve Therapy of Chronic Myeloid Leukemia

(2009) Natalia L. Komarova et al.   PLoS One